StemBioSys

StemBioSys is a private, revenue-generating company founded in 2008 that operates as a platform and tools provider within the cell and gene therapy sector. Its primary innovation is the CELLvo™ Matrix platform, a cell-derived extracellular matrix product that aims to recapitulate the native stem cell niche, promoting cell maturation and function for more predictive assays. The company has demonstrated significant application in maturing induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for cardiotoxicity screening and is expanding into other cell types like neurons and chondrocytes. StemBioSys leverages a collaborative business model, partnering with research institutions and other tool companies to validate and disseminate its technology.

CELLvo™ cell-derived extracellular matrix platform designed to recapitulate the biochemical, structural, and mechanical cues of the native stem cell niche for improved cell culture and maturation.

Competes against dominant substrate providers like Corning (Matrigel) and Thermo Fisher, as well as other specialty ECM and synthetic hydrogel companies. Differentiation is based on the biological relevance and intact nature of its cell-derived matrix, with a focus on specific high-value applications like cardiomyocyte maturation where it has published validation.